Replies to post #211064 on Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

"Management believes that the Company’s market capitalization has not yet reflected the value created by this accomplishment given the fact that there are no competing treatments in an untapped and enormous market. One need only speak with a radiation oncologist to realize the great need to protect against SOM of any origin and the potential sales for such a drug. Recent analyst reports estimate the global OM market at $1-2 billion per year."


So undervalued. Let's start by working our way over $5. Still so much to look forward to.

$IPIX Happy New Year!!

Message in reply to:

Meat on this bone: “Meeting the primary endpoint of reduced incidence of SOM in this Phase 2 study was far more challenging than approaches taken for other drugs in development for this notoriously difficult indication. This feature of Brilacidin-OM greatly differentiates it from other experimental drugs that only address time to onset and duration of SOM. The Company believes our clinical results provide a clear path for expedient development and eventual marketing, which would represent the first drug of its kind to garner FDA approval. These study results position the Company as a global leader in developing a drug to prevent the onset of SOM. Management believes that the Company’s market capitalization has not yet reflected the value created by this accomplishment given the fact that there are no competing treatments in an untapped and enormous market. One need only speak with a radiation oncologist to realize the great need to protect against SOM of any origin and the potential sales for such a drug. Recent analyst reports estimate the global OM market at $1-2 billion per year. “